Method of diagnosing a dysbiosis

Abstract

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

1 - 22 . (canceled) 
     
     
         23 . A method of diagnosing autism in a subject with IBS, comprising determining an abundance of at least 5 species of bacteria in a sample from the subject, wherein the at least 5 species of bacteria are selected from  Eubacterium hallii, Eubacterium rectale, Lachnobacterium bovis, Lachnoclostridium glycyrrhizinilyticum, Blautia glucerasea, Eubacterium desmolans, Anoxystipes fissicatena, Blautia coccoides, Faecalibacterium prausnitzii, Clostridium symbiosum, Roseburia inulinivorans, Anaerostipes coli, Coprococcus comes, Lachnospira pectinoschiza, Arthrobacter creatinolyticus, Clostridium nexile, Bifidobacterium thermacidophilum, Anaerostipes rhamnosus, Clostridium clariflavum, Blautia wexlerae, Fusicatenibacter saccharivorans, Tolumonas auensis, Ruminococcus gnavus, Peptococcus niger, Dorea formicigenerans, Roseburia intestinalis, Blautia wexlerae, Clostridium populeti, Dorea massiliensis , and  Eubacterium eligens.    
     
     
         24 . The method of  claim 23 , wherein the abundance of at least 10 species of bacteria is determined. 
     
     
         25 . The method of  claim 23 , wherein the abundance of at least 20 species of bacteria is determined. 
     
     
         26 - 28 . (canceled) 
     
     
         29 . A method of treating a subject with a autism, comprising diagnosing the subject according to the method of  claim 23 , and administering a composition to the subject which increases and/or decreases the abundance of one or more species of bacteria in the subject, thereby treating the subject. 
     
     
         30 . The method of  claim 29 , wherein the composition is a nutraceutical. 
     
     
         31 . The method of  claim 29 , wherein the composition is a probiotic. 
     
     
         32 . The method of  claim 29 , wherein the composition is a faecal microbiota transplant. 
     
     
         33 . A method of monitoring effectiveness of the treatment of  claim 29 , comprising measuring the abundance of one or more species of bacteria in a sample from the subject, wherein an increase and/or decrease in the abundance of one or more species of bacteria is indicative of the effectiveness of the treatment. 
     
     
         34 . A method of determining a suitable treatment for a subject with autism, comprising diagnosing the subject according to the method of  claim 23 , and determining a suitable treatment based on the results of the determination of subtype of IBS or diagnosis. 
     
     
         35 . The method of  claim 34 , wherein the subject is a human 
     
     
         36 . The method of  claim 35 , wherein the subject has previously been administered a chemotherapy or an antibiotic. 
     
     
         37 . The method of  claim 23 , wherein the sample is a faecal sample.